M1/M2 macrophage-targeted nanotechnology and PROTAC for the treatment of atherosclerosis

Macrophages play key roles in atherosclerosis progression, and an imbalance in M1/M2 macrophages leads to unstable plaques; therefore, M1/M2 macrophage polarization-targeted treatments may serve as a new approach in the treatment of atherosclerosis. At present, there is little research on M1/M2 macr...

Full description

Saved in:
Bibliographic Details
Published in:Life sciences (1973) 2024-09, Vol.352, p.122811, Article 122811
Main Authors: Ma, Yupeng, Yang, Xiaofan, Ning, Ke, Guo, Haidong
Format: Article
Language:English
Subjects:
Animals
Atherosclerosis
Atherosclerosis - drug therapy
Atherosclerosis - immunology
Humans
Macrophage
Macrophages - drug effects
Macrophages - metabolism
Nanotechnology
Nanotechnology - methods
PROTAC
Proteolysis - drug effects
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Macrophages play key roles in atherosclerosis progression, and an imbalance in M1/M2 macrophages leads to unstable plaques; therefore, M1/M2 macrophage polarization-targeted treatments may serve as a new approach in the treatment of atherosclerosis. At present, there is little research on M1/M2 macrophage polarization-targeted nanotechnology. Proteolysis-targeting chimera (PROTAC) technology, a targeted protein degradation technology, mediates the degradation of target proteins and has been widely promoted in preclinical and clinical applications as a novel therapeutic modality. This review summarizes the recent studies on M1/M2 macrophage polarization-targeted nanotechnology, focusing on the mechanism and advantages of PROTACs in M1/M2 macrophage polarization as a new approach for the treatment of atherosclerosis.
ISSN:0024-3205
1879-0631
1879-0631
DOI:10.1016/j.lfs.2024.122811